Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors

Acta Haematol. 2017;138(3):140-142. doi: 10.1159/000477893. Epub 2017 Sep 5.

Authors

Yasuhiro Maeda¹, Atsushi Okamoto, Shin-Ichiro Kawaguchi, Akiko Konishi, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai, Terufumi Yamaguchi

Affiliation

¹ Department of Hematology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan.

PMID: 28869927
DOI: 10.1159/000477893

No abstract available

MeSH terms

Edema / etiology
Humans
Imatinib Mesylate / adverse effects
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Medication Adherence
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
nilotinib